{"preliminary_commentary":{"by_channel":{"x_thread":8,"youtube":2,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05726864\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"AMPLIFY-7P","nct_id":"NCT05726864","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=amplify-7p-nct05726864. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"AMPLIFY-7P","arms":[{"description":"ELI-002 Amph-CpG-7909 (10.0mg) admixed with ELI-002 Amph-Peptides 7P (1.4mg) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections for 4 consecutive weeks during the Booster Period (the two periods are separated by 2 months of no dosing)","label":"Phase 1A: ELI-002 7P (Low Peptide dose)","type":"EXPERIMENTAL"},{"description":"ELI-002 Amph-CpG-7909 (10.0mg) admixed with ELI-002 Amph-Peptides 7P (4.9mg) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections for 4 consecutive weeks during the Booster Period (the two periods are separated by 2 months of no dosing)","label":"Phase 1A: ELI-002 7P (High Peptide dose)","type":"EXPERIMENTAL"},{"description":"The ELI-002 7P dose selected during the Phase 1A portion of the study will be administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections for 4 consecutive weeks during the Booster Period (the two periods are separated by 2 months of no dosing)","label":"Phase 1B: ELI-002 7P","type":"EXPERIMENTAL"},{"description":"The ELI-002 7P dose selected during the Phase 1A portion of the study will be administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections for 4 consecutive weeks during the Booster Period (the two periods are separated by 2 months of no dosing)","label":"Phase 2 randomized: ELI-002 7P","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-11","type":"ESTIMATED"},"conditions":["Pancreatic Ductal Adenocarcinoma","Colorectal Cancer","KRAS G12D","KRAS G12R","KRAS G12V","KRAS G12A","KRAS G12C","KRAS G12S","KRAS G13D","NRAS G12D","NRAS G12R","NRAS G12V","NRAS G12C","NRAS G12S"],"enrollment":{"count":158,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"ELI-002 7P","otherNames":[],"type":"DRUG"}],"last_update":"2026-07-10","lead_sponsor":"Elicio Therapeutics","official_title":"First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2026-04-20","type":"ACTUAL"},"primary_outcomes":[{"measure":"Phase 1: Evaluate the safety of ELI-002 7P","timeFrame":"28 days after the first dose of ELI-002 7P"},{"measure":"Phase 2: Compare ELI-002 7P versus standard of care (SOC; observation) in DFS (disease free survival)","timeFrame":"After the last radiographic assessment at Visit 26 (Week 150)"}],"references":[],"start_date":{"date":"2023-04-14","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors","url":"https://clinicaltrials.gov/study/NCT05726864"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/amplify-7p-nct05726864"}